Health Robotics today announced that it recently signed an exclusive distribution agreement for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies with Israel-based medical technology leader Gamida MedEquip Ltd. This partnership represents Health Robotics’ market entry into its 17th new country over the past 20 months, persisting on its worldwide quest to pervasively provide safe and cost-effective Intravenous (IV) Admixture Compounding Automation to hospitals all over the world.
“Gamida is very pleased to offer Health Robotics’ unique technology to Israel’s top medical centers, which have been awaiting for quite a long time to benefit from these technology solutions, much like Oncology patients and Pharmacological teams all over the world have been enjoying with Health Robotics’ CytoCare since 2007”, stated Moshe Reuveni, Gamida MedEquip’s Managing Director.
CytoCare is the first and only robotic system proven to work anywhere in the world for the safe and sterile preparation of Hazardous Intravenous Admixtures, including Chemotherapy, Monoclonal Antibody Therapy, and Gene Therapy. With 67 installations currently under contract in 17 countries, CytoCare has long proven its unmatched flexibility to adapt to diverse pharmacy workflows and proprietary IV consumables in 4 continents. While several companies attempted the development of Chemotherapy Robotics as far back as 22 years ago, Cytocare is still the only robot that has been able to break the entry-barrier into the Intravenous Chemotherapy Automation Sector.
“Since I personally witnessed two years ago at Hadassah Medical Center the outstanding charity-based care delivered to both Palestinian and Israeli Cancer patients, it has been a long time coming for Health Robotics to be in a position to finally deliver our unique technology to tertiary healthcare centers in Israel such as Hadassah and Sheba Medical Center, which had both expressed high interest in our world-leading products a couple of years ago. After an unusually arduous and time-consuming process to find a service partner in Israel, thanks to Gamida, finally Health Robotics is able to deliver our products and services in Israel. My final selection of Gamida over Teva, Lapidot, and several other Israeli-based companies that had entered into negotiations for Health Robotics’ exclusive distribution rights in Israel puts an end to a 2-year period of waiting by Israel’s top medical centers”, stated Gaspar DeViedma, Health Robotics’ Executive Vice President.
==========
Health Robotics Announces Termination of its Distribution Contract with McKesson Corporation in North America
Health Robotics today announced that earlier last week, it served proper notice to McKesson of the immediate termination for cause of their exclusive CytoCare distribution and services contract in North America, as well as the termination for cause of their non-exclusive distribution agreement for i.v.STATION and i.v.SOFT within a subset of McKesson Automation’s customers.
Health Robotics does not expect this early termination to have a material impact on its overall North American installations given the fact that McKesson’s contracts represented less than 10 % of all Health Robotics’ contracted installations in the USA and Canada since the companies executed their initial IV Automation agreement in August 2009.
More specifically, i.v.STATION and i.v.SOFT customers should not be disrupted at all by this termination due to the fact that 100% of these installations were contracted for and implemented by non-McKesson Health Robotics’ partners and their associates, who will continue to support these i.v.STATION and i.v.SOFT customers without pause.
Until further notice and pending regulatory compliance review, CytoCare customers that have contracts with McKesson Automation should refer their questions about ongoing maintenance and support to McKesson Corporation. Additional non-McKesson CytoCare customers in North America may continue to obtain support from other Health Robotics’ channel partners, whose roles may now be expanded as a result of the early termination of the McKesson contract. Health Robotics is committed to quickly reviewing and revamping its channel partner strategy for this complex sector in North America, as well as reaching an agreement with McKesson for the continued support of its customers.